Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07615426 · ClinicalTrials.gov registry record · Phase 1
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
A Phase 1 study, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT07615426 is a Phase 1 study that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 64 participants.
The verdict
NCT07615426, a Phase 1 study, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.
Interventions
- DRUG Placebo
- DRUG Aticaprant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2027-07-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07615426
The ClinicalTrials.gov registry entry for NCT07615426 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07615426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07615426 about?
NCT07615426 is a clinical study titled "A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia". The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.
What is the current status of trial NCT07615426?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2026-03-02. Estimated completion is 2027-07-05.
What interventions are being tested in trial NCT07615426?
The interventions under investigation include: Placebo (DRUG), Aticaprant (DRUG).
Who is sponsoring clinical trial NCT07615426?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.